Albert Bourla said Pfizer is being "frugal" with investments because of the uncertainty surrounding tariffs.

Unlike other companies grappling with evolving trade policy, Pfizer didn't revise its full-year outlook Tuesday.

Pfizer on Tuesday reaffirmed its outlook for the year, and announced another round of cost cuts as the beleaguered drugmaker ...

The cuts aim to help Pfizer recover from the rapid decline of its Covid business and stock price over the last few years, and ...

Last week, Pfizer announced that it would no longer develop danuglipron, a daily GLP-1 weight-loss drug which investors were excited about as a potential blockbuster for the company. This wasn't ...

Pfizer (PFE) reported mixed first quarter earnings Tuesday, as the company focuses on gaining investor interest in its near-term pipeline amid a volatile macro environment in the markets.

The company’s CEO said he’s had “productive discussions” with Trump administration officials on a recently launched trade ...

Pfizer is ending the development of its potential once-daily pill treatment for obesity before venturing into the biggest and most expensive level of clinical testing. The drugmaker said Tuesday ...

helped bring significant capital back to the company. Tax cuts good, tariffs bad: Pfizer CEO Albert Bourla in Davos on Jan. 23, 2025. (Fabrice Coffrini/AFP via Getty Images) · FABRICE COFFRINI ...

Like his Big Pharma peers, Pfizer (PFE) CEO Albert Bourla is waiting ... components are being produced in the US, but said the company has contingency plans in place. "If there are tariffs ...

A company spokeswoman said the decision announced Monday meant Pfizer would also stop testing danuglipron in combination with other drugs to treat obesity. Shares of New York-based Pfizer Inc ...